Pazopanib is a specialty chemical and small-molecule tyrosine kinase inhibitor (TKI) used primarily in pharmaceutical research and development for oncology applications. It targets multiple kinases involved in tumor angiogenesis and proliferation, such as VEGFR, PDGFR, and c-Kit. As a research reagent, it is supplied as a white to off-white solid with purity ranging from 99-100%. Molecular formula: C₂₁H₁₅N₇O₂S; molecular weight: 473.55 g/mol; CAS number: 444731-52-6. In clinical contexts, it is investigated for treating advanced renal cell carcinoma and soft tissue sarcoma in patients post-chemotherapy, administered orally. Researchers should handle it with care, monitoring for potential cytotoxicity, and consult safety data sheets for storage and usage guidelines.